1 / 21

Review Considerations on Source Plasma Vaccination Programs

Review Considerations on Source Plasma Vaccination Programs. Judy Ellen Ciaraldi BS, MT(ASCP)SBB, CQA(ASQ) CBER, OBRR, DBA September 16, 2009. Outline. Considerations on how to submit for a vaccination program when using: Licensed vaccines according to package insert

ahava
Download Presentation

Review Considerations on Source Plasma Vaccination Programs

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Review Considerations onSource Plasma Vaccination Programs Judy Ellen Ciaraldi BS, MT(ASCP)SBB, CQA(ASQ) CBER, OBRR, DBA September 16, 2009

  2. Outline • Considerations on how to submit for a vaccination program when using: • Licensed vaccines according to package insert • Licensed vaccines not according to package insert • Unlicensed vaccines • Medical oversight • CBER review of vaccination programs

  3. Approved Licensed Vaccine Programs • Tetanus Toxoid • Hepatitis B • Rabies • Smallpox (Vaccinia) • Anthrax • Influenza • Varicella • Material used for immunization must be licensed or approved by CBER (640.66)

  4. Submitting Vaccination Programs • Vaccination programs have been approved by CBER • Vaccination programs are “site-specific” approvals • Contractual arrangements are possible • Perform injections • Collect plasma

  5. Submitting Vaccination Programs (cont.) • If using licensed vaccine according to package insert for the: • Injection volume • Administration route • Injection schedule, including boosters • Typically we have reviewed these as a CBE30 Supplement (601.12(c)) • If approved for specific vaccine and changing vaccine manufacturer but using it according to package insert • If no changes to SOPs – Annual Report (601.12(d)) • If revise SOPs to incorporate new package insert – CBE30 Supplement

  6. Submitting Vaccination Programs (cont.) • If using licensed vaccine but varying from package insert for injection volume, administration route, injection schedule, including additional boosters • We have typically reviewed these as a PAS Supplement (601.12(b)) • Injection protocol is studied under an IND • If using an unlicensed vaccine • We have typically reviewed these as a PAS Supplement (601.12(b)) • Injection protocol is studied under an IND

  7. Submission Content The following items have typically been included in a vaccination program submission: • Forms: 356h and 2567 • Applicant name and license number • Contact name and information • Facility name, address, and registration number • May reference previously approved SOPs, forms, labels (include reference number for approvals) • Medical oversight, use of a physician substitute

  8. Submission Content (cont.) The following items have typically been included in a vaccination program submission (cont.): • Vaccination program SOPs that include • Donor selection (606.100(b)(1)) • Vaccination procedures (640.66) • Handling of adverse events (606.100(b)(9)) • Contractor information • Informed consent form (640.61 & 640.72(a)(3)) • Immunization forms (blank) • Labels (640.70) • Package insert for vaccine

  9. Medical Oversight(640.62 and 640.66) • Qualified licensed physician must be on premises when immunizations are performed • Qualified licensed physician must select and schedule the injection • Qualified licensed physician must evaluate donor’s clinical response • Administration of vaccine may be performed by licensed physician or trained person under physician’s supervision

  10. Medical Oversight (cont.) • Blood Memorandum: Physician Substitutes (8/15/88) • Appropriately trained physician substitute may perform some of the physician’s duties • Physician substitute may administer and supervise approved vaccine immunization programs (needs additional training) • Physician does not need to be on premises during injection but is still responsible for • Weekly evaluation of immunization records • Approval of injections

  11. Medical Oversight (cont.) • CBER has approved physician substitute to assume additional responsibilities in vaccination programs as alternative procedure to 640.66 under the provisions of 640.120 when: • Donors meet all donor suitability criteria • Vaccine is licensed by FDA • Vaccine is administered according to package insert • With this approval, physician substitute may review clinical responses and schedule injections • Physician still responsible for direction and control of vaccination program and for reviewing adverse reactions

  12. SOPs • Immunization procedures must be on file at centers where immunizations are performed (640.66) • Describe medical responsibilities (640.62) • Donor selection procedures (606.100(b)(1)) • Donors must meet all donor suitability criteria in 640.63 & 650.65 • Physical exam must occur within 1 week before first immunization unless active donor (640.63(b)(2)) • Medical staff must approve donor’s participate in the program (640.63(a))

  13. SOPs (cont.) • Vaccination procedures typically include: • Preparation of injection • Injection volume and schedule, including any boosters allowed, administration route • When titrations will be performed • Handling and storing of vaccine vials • Adverse reactions procedures (606.100(b)(9)) • Vaccine Adverse Event Reporting System (VAERS) • Medical oversight (640.62) • Records maintained (640.72(d)) • Proper documentation procedures

  14. Contractor Information • Name and license number • Address and registration number • List activities done under contract • Where records maintained • Describe quality oversight of contractor • Both injection facility and collection center must be approved for vaccination program; both parties are participating in vaccination program

  15. Informed Consent In addition to the requirements in 640.61, the approved informed consent should include: • Volume, route and schedule of injections • Criteria for discontinuation from program • Participate in only one immunization program at a time • May not be eligible for other donation programs • Adverse reactions consistent with package insert • Restrictions for female participants

  16. Immunization Forms The immunization forms in approved submissions have typically included the following information: • Donor name, ID number (640.72(b)) • Injection preparation – date, employee name, visual inspection • Injection – date, employee name, route, volume, facility • Vaccine - name, lot number, expiration date • Physician/physician substitute approval (640.72(a)(4)) • Adverse reactions (640.72(d)) • Evidence of QA review (606.100(c))

  17. Labels • May be made into injectable and noninjectable products • Label must state immunizing antigen (640.70(a)(7)) • Separate label for each vaccine and intended use (and facility, if applicable)

  18. CBER Review of Vaccination Programs • Pre-approval inspection is • Not required if implemented in an approved center • Required if implemented in new center • Vaccination procedures should be consistent with package insert • Approved informed consents typically contain the adverse events described in the package insert • Informed consent includes recommendations in guidance document • Forms contain all information

  19. CBER Review of Vaccination Programs (cont.) • Procedures for donor selection, adverse events and medical oversight are consistent with regulations and include all steps to be followed (606.100) • Physician substitute has necessary training (606.20) and if appropriate, 640.120 approval to select and schedule injection • Procedures for handling and storing vaccine vials are consistent with package insert • Labels consistent with 640.70 • Includes the immunizing antigen (640.70(a)(7)) • All facilities (including contractors) are FDA registered (607.20) and should have acceptable compliance checks

  20. Investigational Vaccine Programs • To distribute Source Plasma in interstate commerce collected as part of an IND program • Source Plasma procedures and labels must be approved • Labels should contain IND number • Collection must occur under cGMPs in facility with approved vaccination program • IND review may include clinical reviewers from either OBRR and OVRR • Contact Office of Communication, Outreach and Development (OCOD) for information on submitting an IND at 301-827-2000

  21. References • Blood Memorandum: Physician Substitutes (8/15/88) • http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/OtherRecommendationsforManufacturers/MemorandumtoBloodEstablishments/default.htm • Guidance for Industry: Informed Consent Recommendations for Source Plasma Donors Participating in Plasmapheresis and Immunization Programs (8/8/07) • http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm073433.htm

More Related